Biotechnology company with a recent SEC Form D offering.
Biotechnology company headquartered in San Diego, CALIFORNIA. Filed SEC Form D on 20260904 for a $25.0M Regulation D offering.
Biotech📍 San Diego, CALIFORNIA
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Gossamer Bio going public?
No. Gossamer Bio is private and has not filed to go public. There is no S-1 on file.
What is Gossamer Bio's valuation in 2026?
No confirmed valuation is on record for Gossamer Bio. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Gossamer Bio filed an S-1?
No public S-1 is on file for Gossamer Bio.
How much has Gossamer Bio raised?
Gossamer Bio has raised $25M in total, most recently a Form D filing of $25M in 20260904.
Is Gossamer Bio publicly traded — can you buy Gossamer Bio stock?
No. Gossamer Bio is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Gossamer Bio on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
HQ
San Diego, CALIFORNIA
Total Raised
$25M
Growth
Filed SEC Form D on 20260904 for $25.0M Regulation D offering
Last Round
Form D filing — $25M (20260904)
IPO Status
private
Fundraising Status
Form D filing · $25M
privateTotal raised $25M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Form D filing
$25M
20260904
—
—
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
2
1 active · 1 recruiting
Lead phase
Phase 3
most advanced registered study
Focus areas
Pulmonary Arterial Hypertension
Latest trial start
2024-09-03
Name-verified against lead sponsor "Gossamer Bio USA, Inc." on ClinicalTrials.gov as of 2026-10-24. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
▲ Hiring uptrend
+100% vs 2026-09
Open roles
2
via greenhouse
Product-build share
0%
engineering, research, product, design
Trajectory
expanding
go-to-market push — Only 0% of open roles build product — hiring is concentrated in sales/marketing/ops (1 of 2 open roles are marketing).
No tracked executive churn; open roles trending up.
Counted from Gossamer Bio's live job board as of 2026-10-08; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
BiotechForm DRecently Funded
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.